Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Andrea Moyer

Cardiovascular Disease Chesterfield, MO Medical Doctor

NPI 1659318996 CMS profile 165227

222 S Woods Mill Rd, Suite 500 North, Chesterfield, MO 63017

Open in the dashboard

General payments

$807

43 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Andrea Moyer of Chesterfield, MO is reported in the CMS Open Payments database as having received $807 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $19 1
2021 General $197 8
2020 General $134 7
2019 General $457 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Moyer
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Andrea Moyer were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Andrea Moyer Cardiovascular Disease median Middle half National median
2019 $457 $450 $127–$1,392 $163
2020 $134 $242 $77–$751 $114
2021 $197 $335 $101–$1,037 $132
2022 $19 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Medtronic, Inc. $107 2 payments
  2. Boston Scientific Corporation $101 5 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $80 5 payments
  4. Abbott Laboratories $65 4 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $64 4 payments
  6. Regeneron Healthcare Solutions, Inc. $58 3 payments
  7. Novartis Pharmaceuticals Corporation $57 4 payments
  8. Sanofi-Aventis U.S. LLC $41 3 payments
  9. Z-Medica, LLC $39 1 payment
  10. Janssen Pharmaceuticals, Inc $38 2 payments
  11. Other $157 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $768 42 payments
  2. Consulting Fee $39 1 payment
Products named General payments · program years 2019–2022
  1. Micra $107 2 payments
  2. JARDIANCE $80 5 payments
  3. LifeVest $64 4 payments
  4. PRALUENT $58 3 payments
  5. ENTRESTO $57 4 payments
  6. PRADAXA $51 3 payments
  7. WATCHMAN $50 2 payments
  8. MULTAQ $41 3 payments
  9. QuikClot $39 1 payment
  10. Control+ $39 1 payment
  11. Other $337 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

4,965

Median for Cardiology: 2,533

Drug cost

$1,176,645

Median for Cardiology: $485,213

Branded share of claims

32.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 512 $554,156
Entresto Sacubitril/Valsartan Brand 230 $245,108
Jardiance Empagliflozin Brand 184 $158,304
Xarelto Rivaroxaban Brand 61 $68,584
Farxiga Dapagliflozin Propanediol Brand 42 $41,598
Repatha Sureclick Evolocumab Brand 34 $23,635
Brilinta Ticagrelor Brand 29 $17,830
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 68 $14,942
Amiodarone Hcl Generic 134 $4,972
Dofetilide Generic 22 $4,594

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$107,895

Medicare's payments for the services billed

Medicare patients

1,028

Average age 76

Services billed

2,494

541 women, 487 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 50%
Heart failure 48%
Atrial fibrillation 45%
Chronic kidney disease 42%
Diabetes 37%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record